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Onset of clinical immunity to Plasmodium falciparum occurred among Javanese migrants to Indonesian Papua.
Surveillance of the 243 migrants investigated began on the day of their arrival in Indonesian Papua and continued
for 33 months. Asexual parasitaemia without fever constituted objective evidence of clinical immunity. Compared
with rst infection, the odds ratio (OR) for not having fever at the fourth infection within 24 months was 3.2
[95% condence interval (CI)=1.03–10.2; P=0.02]. The corresponding OR with fewer infections within 24
months was not distinguishable from 1.0. The level of the fourth parasitaemia within 24 months (N=58) was
classied as ‘high’ or ‘low’ in relation to the median count at rst infection (840 parasites/ml; N=187). Fourth
parasitaemias that were low — but not those that were high (OR=1.8; CI=0.6–5.4; P=0.35) — were associated
with dramatic protection from fever (OR=31; CI=3.5–1348; P=0.0001). Among the adult subjects, the
risk of fever with low parasitaemia was signicantly higher at the rst infection than at the fourth (OR=12.6;
CI=1.7–530; P=0.005), indicating the development of clinical immunity. A similar but less marked pattern
appeared among the children investigated (OR=6.5; CI=0.8–285; P=0.06).
Naturally acquired immunity to Plasmodium throughout much of sub-Saharan Africa
exhibit such immunity. Although nearly con-falciparum renders an otherwise debilitating
tinuously infected and often parasitaemic,and potentially deadly infection relatively
severe disease only occurs very rarely in theseinnocuous. Older children and adults exposed
subpopulations (McGregor, 1952). In con-to uninterrupted heavy exposure to infection
trast, infants and very young children in the
same region account for the majority of the
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1991). Taken together, these observations onset of clinical immunity observed in adult
neurosyphilis patients also appeared to occurindicate that natural protection from para-
sitaemia and symptomatic malaria is the in the naturally exposed, adult migrants.
Malaria-naṏve adults may therefore be capableresult of acquired humoral immunity.
The number and frequency of exposures of acquiring clinical immunity within a year
or two, after just a few infections.required to elicit clinical immunity are not
known. The results of experiments con- Those attempting to develop vaccines
to prevent the high malaria-attributableducted when malaria was used to provide
therapeutic relief from human neurosyphilis mortality and morbidity occurring in sub-
Saharan Africa need to know the factors that(Chernin, 1984; Collins and JeVery, 1999)
demonstrated the onset of clinical immunity determine when and if clinical immunity
to P. falciparum malaria will develop in anafter only four to six challenges (Ciuca et al.,
1934). In sub-Saharan Africa, however, individual. They hope to produce vaccines
that will evoke, in susceptible children, theclinical immunity only appears to develop
after 5–15 years of continuous and heavy naturally acquired protection observed in
adults (Miller and HoVman, 1998), generallyexposure to infection. The relatively slow
onset of clinical immunity in Africans has assuming that children develop sympto-
matic malaria simply because they have hadbeen attributed to the antigenic repertoire
of the parasite and the many heterologous insuYcient cumulative exposure to malarial
antigens (Good et al., 1998; Plebanski andstrains of malarial parasite present in Africa
(McGregor, 1987; Day and Marsh, 1991; Hill, 2000). Post-infection morbidity, how-
ever, may not reect inadequate experienceNewbold et al., 1997). The challenge series
in neurosyphilis patients was with homo- with malarial antigens but inappropriate
immune responses, driven by intrinsic factorslogous strains whereas, presumably, a human
living in Africa must experience very many linked to the age of the host.
The present, longitudinal study on theheterologous infections to acquire immuno-
logical memory of suYcient diversity to sup- onset of clinical immunity to P. falciparum
malaria was conducted as a follow-uppress any given local strain of the parasite.
From this perspective, naturally acquired to the cross-sectional studies underpinning
the hypothesis of age-dependent, acquiredimmunity represents the cumulative product
of many years of uninterrupted heavy immunity (Baird et al., 1991, 1993). After
screening out people who had resided out-exposure to infection by P. falciparum. This,
in part, explains the long-standing reluctance side of Java or within the few regions of Java
with substantial risk of malaria (Baird et al.,of vaccine developers to examine natural
immunity as a model of protection. The 1996), a cohort of 243 Javanese migrants
was recruited, on the day the migrantsresults of studies in Indonesian Papua, how-
ever, do no support the view that cumulative arrived in Indonesian Papua, and followed
for 33 months. This approach allowed theexposure to P. falciparum infection is the
primary determinant of clinical immunity to eVects of age and cumulative exposure to
infection, upon the onset of clinical immunitythis parasite. Age-dependentclinical immunity
to P. falciparum malaria developed in non- to P. falciparum malaria, to be separated.
immune migrants to Indonesian Papua
(formerly known as Irian Jaya) within a
year or two of their arrival (Baird et al., SUBJECTS AND METHODS
1991, 1993). This clinical immunity was
apparently the product of recent heavy Study Site
The study site was the transmigration villageexposure and intrinsic determinants related
to age, independent of a history of chronic designated Satuan Permukiman (Settlement
Unit) 2 (SP2) by the Indonesian authoritiesexposure (Baird, 1995, 1998). The rapid
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that built it. The precise location and nature another was considered a recrudescence and
not counted in the sequence. Secondly, eachof the study site have been detailed else-
where (Krisin et al., 2003). In brief, SP2 enumerated new infection was classied as
febrile or afebrile. The classication ‘febrile’is located near the Pacic coast in the
Bonggo sub-district of north–eastern Papua, was always supported by a recorded axillary
temperature of >37.5°C. The classicationIndonesia, about 150 km west of the city of
Jayapura. The village, which covers an area ‘afebrile’ was supported by a normal axillary
temperature or by the detection of para-of about 4 km2 , consists of 300 identical
wood-plank houses with tin roofs, and elds sitaemia in a routine smear of blood from a
subject who appeared healthy and reportedfor the cultivation of subsistence and cash
crops such as melon, papaya, soy, peanut no illness. The health workers who collected
the routine smears worked under strict ordersand maize. At the time of the present study,
dense forest surrounded the cleared area of to bring any ill subject to the study clinic
in SP2, for examination. Throughout thethe village.
study, the same open-ended question — ‘Do
you have any symptoms?’ — was used bySubjects
the health workers on their home visits, toThe details of recruitment, enrolment,
avoid bias. Finally, each new infection wasfollow-up and the epidemiology of malaria
classied as a low parasitaemia (if the levelin the SP2 cohort have been described else-
of parasitaemia was lower than the medianwhere (Krisin et al., 2003). In brief, 243
rst-infection level among all the subjects)subjects aged 6–12 years ( N=97) or 20–58
or a high parasitaemia.years ( N=146) were successfully enrolled.
After 33 months of follow-up, 159 (69
children and 90 adults) remained under Statistical Analysis
observation. Almost all losses to follow-up Results were expressed as frequencies and
were the result of migrants deciding to analysed using Mantel–Haenszel tests or
return to Java. x2 tests with Yates’ correction. Fisher’s
exact tests were used when expected cell
values were below 5.0. A P-value of å0.05Follow-up
was considered indicative of statistical signi-Each week, the homes of the subjects were
cance. All the analyses were carried outvisited three times, so that the health status
using version 9.0 of the SPSS (SPSSof each subject could be determined. Smears
Inc., Chicago, IL) or version 6.0 of the Epiwere made of blood samples collected every
Info (Centers for Disease Control and2 weeks (without regard to illness) and also
Prevention, Atlanta, GA) software packages.immediately from any subject who com-
All of the results presented below refer toplained of illness. The smears produced
P. falciparum infection.routinely every 2 weeks were not examined
immediately but stained, stored and trans-
ported to Jakarta for reading. RESULTS
Exposure Threshold for the Onset ofClassication of Infection
All cases of malaria were microscopically con- Clinical Immunity
Parasitaemia without fever constitutedrmed. A three-tiered classication scheme
for parasitaemia was employed. Firstly, objective evidence of clinical immunity to
P. falciparum and the Figure illustrates thethe infection sequence was enumerated,
separately for P. falciparum and P. vivax odds ratios (OR) for not having fever after
experiencing the second, third and fourth(e.g. ‘fourth infection with P. falciparum’);
a parasitaemia detected å28 days after infections within 6, 12 or 24 months. As the
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FIG. The lines indicate the odds ratios for fever, relative to the rst infection, during the second, third and
fourth infections by P. falciparum within 6 (d), 12 (h) or 24 (s ) months. The additional points show the
corresponding P-values.
rst infection constituted the reference point Three infections in the same interval only
provided marginally signicant protectionfor the OR in the subsequent infections,
the rst infection had an OR of 1.0 and a and one or two infections failed to show any
protection from fever with parasitaemia.P-value of 1.0, by mathematical denition.
The second infection within 6, 12 or 24
months was no less likely to cause fever than
the rst: the OR were å1.4 and the P-values Risk of Fever with Low or High
Parasitaemia at First or Fourth>0.2. The third infection within 6 months
also showed no diminished risk of fever Infection
The relationship between risk of fever and(OR=1.0; P=0.9), but when the third
infection occurred later (within 12 or 24 density of parasitaemia (stratied by sequence
of infection) was investigated (Table 1). Atmonths), marginally signicant protection
from fever appeared. The OR for three rst infection, subjects with low parasitaemia
(i.e. with parasitaemias below the medianinfections within 12 months was 1.8 (P=
0.08) — essentially the same as when the rst-infection level of 840 parasites/ml ) were
at the same risk of fever as the subjects withthree infections occurred within 24 months
(OR=1.7; P=0.08). When four infections high parasitaemia (OR=1.24; P=0.916).
In contrast, at fourth infection, the sub-occurred within 12 or 24 months (no subject
experienced four within 6 months), the pro- jects with low parasitaemia were more likely
to be afebrile than subjects with high para-tection from fever markedly improved. The
OR for not having fever at fourth infection sitaemia (OR=21; P=0.0004). When the
risk of fever at rst or fourth infection waswithin 12 and 24 months were 3.2 (P=0.02)
and 3.1 (P < 0.01), respectively. Onset stratied by the density of the concurrent
parasitaemia (Table 2), subjects with highof clinical immunity thus occurred among
members of the SP2 cohort experiencing at parasitaemia were found to be equally likely
to be febrile at rst and fourth infectionleast four infections within 12 or 24 months.
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TABLE 1. Risks of fever, with high- versus low-level parasitaemia, at the rst and fourth infections of the 58 subjects
who had four Plasmodium falciparum infections within 24 months
No. of subjects:
Febrile Afebrile Odds ratio and (95% condence interval) P
first infection
High-level parasitaemia 21 10 1.24 (0.4–4.2) 0.916*
Low-level parasitaemia 17 10
fourth infection
High-level parasitaemia 21 18 21 (2.5–916) 0.0004²
Low-level parasitaemia 1 18
*x2 test with Yates’ correction.
²Two-tailed Fisher’s exact test.
TABLE 2. Risks of fever with high- and low-level parasitaemias, at rst versus fourth infection, among the 58 subjects
who had four Plasmodium falciparum infections within 24 months
No. of subjects:
Febrile Afebrile Odds ratio and (95% condence interval) P
high-level parasitaemias
First infection 21 10 1.8 (0.6–5.4) 0.350*
Fourth infection 21 18
low-level parasitaemias
First infection 17 10 31 (3.5–1348) 0.0001²
Fourth infection 1 18
*x2 test with Yates’ correction.
²Two-tailed Fisher’s exact test.
(OR=1.8; P=0.35) whereas subjects with DISCUSSION
low parasitaemia were far more likely to be
afebrile at the fourth infection than at the In a cohort of 159–243 subjects followed for
rst (OR=31; P=0.0001). 33 months, only 58 subjects experienced
four infections by P. falciparum within any
24-month period. Among these 58 subjects,Age-specic Risk of Fever with Low
signicant protection from fever was onlyParasitaemia at First versus Fourth
observed with the fourth parasitaemia (Fig.).Infection
In SP2 at least, four infections within 2After febrile subjects with low parasitaemias
years therefore appears to be the minimalhad been classied as ‘sensitive’, it became
threshold for the onset of clinical immunityclear that subjects were less likely to be
(as indicated by parasitaemia without fever).sensitive at their fourth infection than at
Although risk of fever was independent oftheir rst. This trend was more marked
the level of parasitaemia at rst infection, atamong the adult subjects than among the
the fourth infection fever occurred almostchildren investigated (Table 3): children were
exclusively among the subjects with high-6.5 times (P=0.06), and adults 13 times
level parasitaemias (Table 1). Among the(P=0.005), less likely to be sensitive at their
subjects with high-level parasitaemias, nofourth P. falciparum infection than at their
rst. protection from fever occurred at the fourth
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TABLE 3. Risks of fever with low-level parasitaemia, at rst versus fourth infection, among the child and adult subjects
No. at:
First infection Fourth infection Odds ratio and (95% condence interval) P
children
Febrile 15 1 6.5 (0.8–285) 0.06*
Afebrile 51 22
adults
Febrile 27 1 12.6 (1.9–530) 0.005*
Afebrile 73 34
*Two-tailed Fisher’s exact test.
infection (relative to the rst), whereas high-level ( N=21) or low-level parasitaemias
( N=1), at their fourth infection (Table 2).marked protection appeared among the sub-
jects with low-level parasitaemias (Table 2). Naturally acquired immunity after four
infections within 24 months was thereforeIf clinical immunity to P. falciparum was
dened by a low parasitaemia without fever, considered to be, as a crude estimate, 62%
eVective in conferring protection from fever.children appeared slightly less likely than
adults to exhibit protection at the fourth Subtlety marked the diVerences in the
onset of clinical immunity between theinfection (Table 3).
Among Javanese migrants to Indonesian children and adults investigated (Table 3).
Because the demography of the migrantPapua, immune responses leading to sup-
pression of parasitaemia are apparently populations limited the availability of younger
subjects, only children aged >5 years atassociated with the onset of clinical immunity.
The level of parasitaemia appeared to be a enrolment were investigated. The youngest
subjects in the study cohort were approach-primary correlate of fever. Even after four
infections within 24 months, subjects with ing 9 years of age when the study ended.
Most of the children in the cohort werehigh-level parasitaemias were at the same risk
of fever as subjects with such parasitaemias well into puberty at that time. Kurtis et al.
(2001) documented the importance of thisat the rst infection. Essentially similar nd-
ings were reported from a cohort of adults developmental event as a determinant of
susceptibility to P. falciparum among Africanin holo-endemic northern Ghana: the OR
for symptoms with high-level parasitaemia children. The fact that the children investi-
gated in the SP2 cohort were relatively old(i.e. >2000 parasites/ml) was 3.2 [95%
condence interval (CI)=1.1–9.1; P=0.01; may have subdued the age-related diVer-
ences noted in the earlier, cross-sectionalOwusu-Agyei et al., 2001]. Naturally acquired
clinical immunity appears to be associated studies from similar populations (Baird et al.,
1991, 1993).with anti-parasite rather than anti-disease
eVectors. In summary, protection from fever
associated with P. falciparum parasitaemiaIn the present study, the onset of clinical
immunity even among the 58 subjects occurred among 62% of Javanese migrants
who experienced at least four P. falciparumwho received suYcient exposure (i.e. four
P. falciparum infections within 24 months) infections within 24 months of arriving in
Indonesian Papua. Protection from feverwas not universal: only 18 of the 58 had low
parasitaemias without fever at their fourth was especially pronounced among subjects
with low-level parasitaemias. These ndingsinfection. The other 40 had high parasitaemias
without fever ( N=18) or were febrile, with support the hypothesis that attributes the
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among six populations with limited histories ofonset of clinical immunity to relatively brief
exposure to endemic malaria. American Journal ofexposure and intrinsic factors that are linked
Tropical Medicine and Hygiene, 49, 707–719.
to age and independent of lifelong exposure
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